Similarly, the vast majority of patients benefiting from genomically-tailored therapy in a recently reported breast cancer trial either had a PIK3CA mutation and received alpelisib, or had BRCA1/2 or similar alterations and received olaparib. This evidence concerns the gene BRCA1 and breast cancer.